BigHat Biosciences
AI-native protein therapeutics designed with autonomous wet-lab data
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
BigHat Biosciences is a clinical-stage biotechnology company in San Mateo, California that designs protein therapeutics by integrating frontier AI with a high-throughput automated wet lab. Its Milliner platform generates experimental antibody data at scale to train and improve design models. Public materials describe a pipeline including BHB810, a CDH17-directed ADC in Phase 1, and collaborations with major pharma. In September 2026 the company announced a $75 million Series C co-led by DFJ Growth and Premji Invest, bringing total funding disclosed to $223 million.
- Website
- bighatbio.com
- Stage
- series-b+
- Location
- San Mateo, California, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Milliner — AI + automated wet lab platform for antibody design · Saas